ClinicalTrials.Veeva

Menu

Bright Light Therapy as Possible Treatment Option for MS-Fatigue

Medical University of Vienna logo

Medical University of Vienna

Status

Unknown

Conditions

Multiple Sclerosis
Fatigue

Treatments

Device: dim red light
Device: bright light therapy

Study type

Interventional

Funder types

Other

Identifiers

NCT04681586
AP18005ONB

Details and patient eligibility

About

This study aims to investigate the effect of a 2-week trial of bright light therapy (BLT, 10.000 lx) on fatigue in multiple sclerosis (MS) patients. In this randomised placebo-controlled trial, the effect of bright light therapy will be compared to dim red light. MS-fatigue is quantified by patients using a visual analogue scale (VAS) and activity levels, subjective and objective sleep parameters and daytime sleepiness are measured.

Full description

Materials and methods:

  • visual analogue scale (4x/day for 6 weeks; measuring fatigue)
  • wrist actigraphy (6 weeks)
  • sleep diaries (6 weeks)
  • polysomnography (2x)
  • multiple sleep latency test (2x)
  • 4 subtests of the TAP (Testbatterie zur Aufmerksamkeitsprüfung; Alertness, Vigilance, Go/No-Go, Split Attention)
  • questionnaires (Fatigue Severity Scale, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, Beck Depression Inventory, Beck Anxiety Inventory, Modified Fatigue Impact Scale, Morningness-Eveningness Questionnaire)

Enrollment

36 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • MS patients who suffer from fatigue
  • Age between 18 and 65 years old
  • FSS Score of 36 or greater
  • ESS Score of 12 or greater
  • MEQ Score between 31 and 69
  • BDI Score lower than 19
  • BAI Score lower than 27
  • EDSS lower than 4

Exclusion criteria

  • sleep disorders (periodic limb movement disorders, obstructive or central sleep apnea, REM sleep behavior disorders)
  • change of antidepressive/fatigue influencing/sleep influencing/photosensizing/MS medication within the preceding 4 weeks
  • clinical MS-relapse within the preceding 4 weeks
  • consumption of alcohol: more than 1 glass per day
  • consumption of caffeine: more than 4 cups per day
  • current shift work
  • Jet lag (travelled across two or more time zones within 90 days before study screening
  • Retinopathy or other visual diseases/abnormalties
  • Traumatic brain injury within the preceding 5 years
  • pregnant or lactating
  • Participation in another clinical trial at the same time

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

36 participants in 2 patient groups, including a placebo group

Bright white light
Experimental group
Treatment:
Device: bright light therapy
Dim red light
Placebo Comparator group
Treatment:
Device: dim red light

Trial contacts and locations

1

Loading...

Central trial contact

Lisa Voggenberger, MSc; Stefan Seidel, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems